<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02020902</url>
  </required_header>
  <id_info>
    <org_study_id>200638</org_study_id>
    <secondary_id>RH01905</secondary_id>
    <nct_id>NCT02020902</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance for Contac Bien Z in Japan</brief_title>
  <official_title>Contac Bien Z Adverse Effect Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-marketing surveillance study on a marketed cetrizine hydrochloride
      formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events after having cetrizine hydrochloride</measure>
    <time_frame>At baseline</time_frame>
    <description>Participants will answer a questionnaire which consists of questions on safety of the marketed cetrizine hydrochloride formulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the marketed cetrizine hydrochloride formulation</measure>
    <time_frame>At baseline</time_frame>
    <description>Participants will answer a questionnaire which consists of questions on their satisfaction after taking the marketed cetrizine hydrochloride formulation. The efficacy will be measured on a 4 point scale (1 Efficacious; 2 Somewhat efficacious; 3 Not efficacious; 4 Not known)</description>
  </secondary_outcome>
  <enrollment type="Actual">1552</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Seasonal Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cetrizine hydrochloride</intervention_name>
    <description>As provided on the patient information leaflet</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who purchase the marketed cetrizine hydrochloride formulation from pharmacy
        stores in Japan.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female participants, between 15-65 years of age, who purchase the marketed
             cetrizine hydrochloride formulation

        Exclusion Criteria:

          -  Who have ever experienced allergic symptoms by taking this medication or any component
             of this medication, piperazine derivative (including levocetirizine, hydroxizine)

          -  Those who have been under 15en diagnosed with kidney disease

          -  Children under 15 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Drug Store Seki</name>
      <address>
        <city>Saitama</city>
        <zip>340-0144</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2013</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

